Australians became familiar with CSL through the pandemic,but as the company emerges from COVID,it has ambitious new plans to disrupt a variety of medical ailments.
The deal will give CSL the exclusive licence to US company Arcturus Therapeutics’ technology in the fields of influenza,COVID-19 and other respiratory diseases.
The biotech giant is entering the arena of iron and kidney disease treatments,but its shares declined on Monday.
Moderna chief Stephane Bancel is thinking well beyond its current COVID vaccines when it comes to the Australian market.
Analysts and experts are starting to run the ruler over the benefits of a new treatment before the FDA on the ASX-listed biotech giant’s bottom line.
Profits at the biotech giant declined in 2022 but boss Paul Perreault is looking beyond plasma collections to his newest purchase.
The biotch giant is expanding its focus to include drugs that treat kidney disease and iron deficiency.
The biotech giant has won a US court appeal that will give it the right to fight for the return of Mexican plasma donors.
The biotech giant has gone on a hiring and training spree to ensure there are enough staff available to man its plasma collection centres.
CSL shares are down 10 per cent year-to-date,but stock watchers see growth ahead for the listed biotech giant on the horizon.
The US government is refusing to back down in a court battle with biotech giant CSL over the legitimacy of Mexican plasma donors.